THALES
1.3.2023 08:01:34 CET | Business Wire | Press release
Thales, the world leader in eSIM management, supports the growth of eSIM-enabled consumer and industrial devices with Google Cloud expertise. Thales' pioneering Cloud solution combines its own security assets with Google's cloud presence in 200 countries to provide enhanced security, flexibility, and service availability to MNOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005040/en/
Thales, a global leader in eSIM management. @Thales
Remote eSIM activation, anytime and anywhere
By 2025, the number of eSIM connections is estimated to reach close to 9 billion1. Fuelled by 5G, the growth in connections is the result of increased connectivity of consumer products such as smartphones, tablets and wearables, and numerous industrial devices. With Thales’ eSIM management platform hosted on Google Cloud completed with Thales digital onboarding solutions, MNOs can offer their subscribers the speed, convenience and efficiency of activating subscriptions remotely. Today, Thales is able to meet high demands from hundreds of customers worldwide, including Telefonica, one of the world's largest telco operators and mobile network providers.
The perfect response to MNOs digital transformation and exponential IoT growth
With easy and secure access to Thales services hosted on Google Cloud, mobile operators can respond immediately to surging demand for eSIM activation and offer their subscribers a full digital experience. Such solutions also provide greater scalability as well as resources mutualisation, enabling mobile operators efficiently and rapidly deploy new services. In terms of security, Thales keeps full control, by designing highly secure end-to-end hardware and software, as well as by storing and managing the secret codes in its secure vaults (secret codes are keys used by devices for eSIM activation to securely access mobile networks). This underpins world-class data privacy, sovereign cloud approach and rigorous defence against cyberattacks.
Certified and sustainable
The eSIM usage has become mission-critical to enable a sustainable access to connectivity for the expanding consumer and industrial IoT. Thales’ integration of global GSMA-certified solution protects MNOs against interruptions in any part of the world. MNOs therefore benefit from outstanding disaster recovery, business continuity and improved quality of services.
Google Cloud’s is today one of the most energy efficient clouds2 in the industry and aims to operate entirely on carbon free energy 24/7 and everywhere in the world by 2030.
“We have been trustfully partnering with Thales for years to address new connectivity challenges and MNO needs with cloud technology. This future-proof solution provides the market with the required flexibility, security, and resilience to meet consumer’s ‘anytime anywhere’ wish, while also addressing new technological requirements. Adding to Google Cloud services, the security aspect brought by Thales and its remote eSIM management leadership, brings relevance and support to MNOs eSIM strategy.” said Amol Phadke, General manager, Global Telecom Industry at Google Cloud
“There is an increasing consumers’ adoption of eSIM enabled phones, wearables and tablets while MNOs are ramping up for the 5G and IoT revolutions. Two years after the announcement of our partnership with Google Cloud, Thales’ pioneering Cloud eSIM solution has reached its full maturity. Our customers can trust us to support them in their eSIM strategy, meeting data privacy regulations as well as protecting them against the most sophisticated cyber threats” said Eva Rudin, VP Mobile Connectivity Solutions at Thales.
1 Counterpoint, eSIM Ecosystem CORE Analysis, May 2022
2 On average, a Google data center is twice as energy efficient as a typical enterprise data center.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations — connectivity, big data, artificial intelligence, cybersecurity and quantum computing — to build a future we can all trust, which is vital to the development of our societies.
The company provides solutions, services and products that help its customers —businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom